Real-world safety experience with Peanut (Arachis hypogaea) Allergen Powder-dnfp in 2500 children with peanut allergy

Ann Allergy Asthma Immunol. 2024 Jun;132(6):778-780. doi: 10.1016/j.anai.2024.02.027. Epub 2024 Mar 11.

Authors

Michele Jara¹, Ekaterina Walker², Stephen Tilles², Aikaterini Anagnostou³

Affiliations

¹ Aimmune Therapeutics, a Nestlé Health Science company, Brisbane, California. Electronic address: Michele.Jara@us.nestle.com.
² Aimmune Therapeutics, a Nestlé Health Science company, Brisbane, California.
³ Division of Immunology, Allergy and Retrovirology, Department of Pediatrics, Texas Children's Hospital, Houston, Texas.

PMID: 38479712
DOI: 10.1016/j.anai.2024.02.027

No abstract available

Publication types

Letter

MeSH terms

Adolescent
Allergens* / immunology
Antigens, Plant / immunology
Arachis* / immunology
Child
Child, Preschool
Desensitization, Immunologic / methods
Female
Humans
Male
Peanut Hypersensitivity* / immunology
Powders

Substances

Allergens
Powders
Antigens, Plant